Infectious disease doctor Dr. Amesh Adalja on several states see spike in coronavirus cases.
A monoclonal antibody cocktail developed by Regeneron and Roche dropped the risk of symptomatic COVID-19 by up to 76% after three days for recently infected individuals not yet experiencing symptoms, according to a press release posted Monday. The drug, REGEN-COV, also significantly reduced duration of symptoms and lowered viral levels, Regeneron said.
REGEN-COV, comprised of casirivimab with imdevimab, has already received emergency use authorization from the FDA in the U.S. Under the current EUA, the combo therapy is approved to treat non-hospitalized adults and adolescents with mild to moderate symptoms of COVID-19 and who are at high risk for developing severe symptoms or the need for hospitalization.
A study has found that an antibody drug produced by Regeneron Pharmaceuticals has reduced the risk of developing symptomatic Covid-19 by up t0 81%. According to the company, there were no hospitalisations of Covid-19 volunteers within the study, compared with four in the placebo group. The Wall Street Journal reports that the study has also shown the drug’s ability to reduce the risk of death or hospitalisation by about 70%. “So far, 21.3% of the U.S. population has been fully vaccinated, and 35.3% has received at least one shot”. Regeneron’s president, George D. Yancopoulos, has said the antibody cocktail may “help provide immediate protection to unvaccinated people who are exposed to the virus.”– Jarryd Neves
Regeneron, Roche injectable antibody drug shows efficacy in preventing Covid-19
A Regeneron Pharmaceuticals antibody cocktail currently authorized for treating Covid-19 now has additional clinical data showing it reduces the risk of infection spread. The drug developer, along with partner Roche, plan to ask regulators to expand the drug’s authorization to include disease prevention.
Shares0
A Covid-19 antibody cocktail developed by Regeneron Pharmaceuticals and Roche has pivotal clinical trial data showing it protected against the spread of infection among people in the same household. The results support use of the drug as a preventative measure in a formulation that’s easier for both physicians and patients.
New Phase 3 trial data finds a single shot of Regeneron s COVID-19 antibody cocktail was able to prevent symptomatic COVID-19 among people exposed to the virus, the company said.
Reply
April 9, 2021
COLORADO SPRINGS, Colo. – Mayor John Suthers announced today his appointment of Mary Weeks as the new Chief Information Officer for the City of Colorado Springs. This appointment is pending confirmation by City Council. Mary Weeks has been with the City of Colorado Springs Information Technology Department since 2013, most recently in the position of IT Business and Operations Manager. Prior to joining the City, Mary spent 24 years in Information Technology with HP and EDS in roles of senior program manager, team manager, project manager, business consultant, application developer and financial analyst.
Subscribe Mary Weeks has been an integral part of the City s IT team for eight years, with increasing amounts of responsibility and expertise, said Mayor John Suthers. She has the respect of her colleagues and an invaluable understanding of the City s IT and cybersecurity environments. We look forward to her leadership as we face the IT challenges of the